Navigation Links
SURPASS Announces Two Strategic Hires in Silicon Valley Facility and Launch of Social Media Accounts
Date:7/17/2014

OSCEOLA, Wis. and MOUNTAIN VIEW, Calif., July 17, 2014 /PRNewswire-iReach/ -- Surpass, Inc. ("Surpass"), a recognized leader in translational preclinical research, today announced the addition of David Craig, a veteran preclinical scientist and expert veterinary interventionalist, and Benigno Mills, a veterinary surgical and interventional specialist, to the Surpass-Silicon Valley Team. In addition, to better serve our clients, we are pleased to announce that Surpass has launched social media accounts on Twitter, Facebook and Google+ to supplement the existing account on Linked In.

Photo - http://photos.prnewswire.com/prnh/20140717/128042

"Surpass is an integrated medical innovation partner for clients in the life-sciences community.  These recent strategic hires are evidence of Surpass' commitment to meet our clients' ever-changing needs - rounding out the Scientific and Veterinary Research Team at our West Coast site. With budgets getting tighter and timelines shorter, clients are looking for their CRO partners to do more. They want expertise in study conduct, execution, and reporting while offering flexibility in a compliant environment. The Surpass team offers customized service at our Midwest and West Coast facilities with expert professionals in surgical and interventional services," said Dr. Tim Pelura, President and CEO of Surpass.

David Craig, BS, Director of Operations and Interventional Services, comes to Surpass with more than 17 years of preclinical research experience, working at multiple domestic and international CROs and large medical device and pharmaceutical companies. Benigno Mills, BS, SRS, Interventional and Surgical Specialist, comes with more than five years of preclinical experience at a local contract research organization.

In addition to the recent hires, Surpass is pleased to announce the expansion of our social media platform to include Twitter, Facebook and Google+. "The world of corporate communications has changed.  As a valued partner, we want to connect with our clients where they are, on Twitter, Facebook and Google Plus in addition to Linked In. We want to provide value and insight for making their jobs easier," said Dr. Pelura.

About Surpass

Our innovative approach to preclinical research goes beyond the ordinary. We're changing the rules for a better way to get from concept to reality.

Surpass is a trusted contract research organization (CRO) with extensive experience conducting medical device, pharmaceutical, biotech and combination product studies with specialized expertise in surgical and interventional procedures. Our testing services include early feasibility, product development, GLP, and physician/clinical training studies. At Surpass, we provide insightful solutions and support every step of the way, offering expert advice and the level of comprehensive support needed to make your study successful – the first time.

Surpass' breadth of case experience in preclinical studies includes feasibility and safety assessments of ablation systems, vascular grafts, orthopedic prostheses, stents, closure devices, valves, infusion pumps, drug coated balloons, neurostimulators, pharmaceuticals, biologics, imaging systems, cardiac assist devices, and more. Whether you are a startup or an established player, Surpass is uniquely qualified to make your study successful. Contact Surpass today at (651) 433-4277 (Greater Twin Cities) or (650) 477-8267 (Silicon Valley).

Visit www.surpassinc.com for more information. Connect with Surpass, Inc. on Linked In, Twitter, Facebook, and Google+.

Media Contact: Denise Forkey, Surpass, Inc., 650-938-2101, dforkey@surpassinc.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Surpass, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. JCB Laboratories Debuts High Tech Monitoring System That Will Further Enhance Patient Safety, Surpass Compounding Pharmacy Standards
2. French Man Surpasses Two Years of Support with SynCardia Total Artificial Heart
3. SynCardia Total Artificial Heart Surpasses 100th Implant of 2013
4. Global Ubiquitin Proteasome Research and Development Market to Surpass $5.5 Billion by 2018: BCC Research
5. YouTube Channel on SEO Tips Surpasses 175,000 Views, Announces JM Internet Group
6. University of Oklahoma Housing and Food Likely to Surpass Budget, My Cleaning Products Recommends Pest Control Products That Could the Department's Spending in Half
7. Lucintel’s Analysis of Growth Opportunities in China’s Composites Industry: Expect Market to Surpass $11 Billion in 2017
8. Butamax Early Adopters Group surpasses capacity targets with addition of Big River; Membership represents 11 production facilities and nearly 900 million gallons of ethanol capacity
9. Accuray Surpasses 600 Installations Globally
10. Pure Energy Group Announces Affiliation with American Biogas Council
11. Roka Bioscience Announces Pricing of Initial Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... Chapel Hill, N.C. (PRWEB) , ... June 27, ... ... of U.S. commercial operations for Amgen, will join the faculty of the ... will serve as adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with ...
(Date:6/24/2016)... -- Regular discussions on a range of subjects including policies, debt ... said Poloz. Speaking at a lecture to the ... pointed to the country,s inflation target, which is set by ... "In certain areas there needs to ... goals, why not sit down and address strategy together?" ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica delle Marche ... with peritoneal or pleural mesothelioma. Their findings are the subject of a new article ... Diagnostic biomarkers are signposts in the blood, lung fluid or tissue of mesothelioma patients ...
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
Breaking Biology Technology:
(Date:4/28/2016)... , April 28, 2016 Infosys ... (NYSE: INFY ), and Samsung SDS, a global ... that will provide end customers with a more secure, fast ...      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) , ... but it also plays a fundamental part in enabling and ...
(Date:4/15/2016)... April 15, 2016  A new partnership announced ... accurate underwriting decisions in a fraction of the ... priced and high-value life insurance policies to consumers ... With Force Diagnostics, rapid testing (A1C, Cotinine ... readings (blood pressure, weight, pulse, BMI, and activity ...
(Date:3/31/2016)... 2016  Genomics firm Nabsys has completed a financial ... Bready , M.D., who returned to the company in ... leadership team, including Chief Technology Officer, John Oliver ... Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys from ...
Breaking Biology News(10 mins):